this with the activities of three other fluoroquinolones: ofloxacin, sparfloxacin and ciprofloxacin.
Introduction
Until the late 1970s, Streptococcus pneumoniae was susceptible to several commonly used antimicrobials, including the penicillins and erythromycin. Since then, however, there has been a slow upward trend in MICs of penicillin for S. pneumoniae, resulting in an increasing prevalence of penicillin resistance worldwide. Recently it has been reported that between 10-50% of S. pneumoniae isolates are no longer susceptible to penicillin. 1 In addition, penicillin-resistant strains are usually resistant to other -lactam antibiotics such as ampicillin, amoxycillin, co-amoxiclav and oral cephalosporins. The existence of such multiply resistant strains is problematic and the choice of alternate antimicrobial therapy must be considered carefully.
Most of the currently available fluoroquinolones have limited activity against S. pneumoniae so they are not used as a first-line therapy for the treatment of such infections. 2 In addition, there have been several reports of pneumococcal bacteraemia in patients while on ciprofloxacin therapy. [3] [4] [5] The new fluoroquinolones, however, show enhanced activity against S. pneumoniae 6 and may be suitable for the treatment of infections caused by this pathogen.
Levofloxacin, the active L-isomer of the racemate ofloxacin, is reported to have high activity against the most common respiratory tract pathogens, including S. pneumoniae (MIC 90 , 1-2 mg/L) and strains that are resistant to -lactams and other antibiotics. 6 The preliminary results of clinical trials using levofloxacin in the treatment of upper and lower respiratory tract infections suggest that it is more effective than ofloxacin and may be tolerated better. [6] [7] [8] [9] [10] [11] In addition, there is evidence to suggest that levofloxacin selects fewer resistant S. pneumoniae variants than other, currently available fluoroquinolones.
Materials and methods

Bacterial isolates
In total, 205 consecutive clinical isolates of S. pneumoniae, collected from 1 September 1996 to 15 September 1996, were tested in this study. These isolates, from routine specimens, were derived from the following sources: blood cultures (44 isolates), cerebrospinal fluid (5), middle ear aspirates (22) , pleural fluids (2), ascitic fluid (1), conjunctiva (10), sputa (101) and other sources (20) . Approximately half of the isolates (101) were penicillin-susceptible (MIC, <0.1 mg/L), 51 were penicillin-intermediate (MIC, 0.1-1 mg/L) and 53 were penicillin-resistant (MIC, >1 mg/L).
All strains were collected from French hospitals participating in the National Co-operative Survey of Pneumococcal Infections. The strains were stored in Brain Heart Infusion (BHI) broth (Difco Laboratories, Detroit, MI, USA) plus 15% glycerol at -80°C.
Antimicrobial agents
The antimicrobial agents used were penicillin G (Hoechst Marion Roussel, Romainville, France), sparfloxacin (Rhône-Poulenc Rorer, Vitry-sur-Seine, France), ciprofloxacin (Bayer Pharma, Puteaux, France), levofloxacin (Hoechst Marion Roussel) and ofloxacin (Hoechst Marion Roussel), supplied as laboratory powders of known potency. Stock solutions were prepared according to manufacturer recommendations.
MIC determination
The MICs of penicillin G and the four fluoroquinolone agents were determined for the 205 strains by the agar dilution method recommended by the Antibiogram Committee of the French Society of Microbiology.
14 The inoculum was prepared by suspending several colonies from an overnight culture of S. pneumoniae in BHI broth supplemented with 10% horse serum. This was shaken for 3 h in a water bath at 37°C. An inoculum of 10 4 -10 5 cfu per spot was delivered with a multipoint inoculator (Serlabo, Bonneuil, France) on to Mueller-Hinton agar (Difco Laboratories, Elancourt, France) plates supplemented with 5% horse blood containing the appropriate antimicrobial concentration. The plates were incubated overnight at 37°C with 5% CO 2 supplementation. Staphylococcus aureus strain ATCC 25923 was used as the control.
The MIC was defined as the lowest concentration of antimicrobial agent to inhibit bacterial growth completely after incubation for 18 h.
Results
The (Tables I-IV) . In contrast, the differences in in-vitro activity observed among the four fluoroquinolones against the 205 strains allowed them to be separated into three groups: sparfloxacin (MIC 50/90 , 0.25 mg/L), ciprofloxacin and levofloxacin (MIC 50 , 0.5 and 1 mg/L, respectively; MIC 90 , 1 mg/L), and ofloxacin (MIC 50 , 1 mg/L; MIC 90 , 2 mg/L).
One of the 205 pneumococcal isolates (0.5%) had a high level of resistance to the fluoroquinolones tested (Table  IV) 
Discussion
The results of this study indicate that, whatever the level of susceptibility to penicillin, sparfloxacin showed the greatest bacteriostatic activity, followed in descending order by ciprofloxacin/levofloxacin and ofloxacin. The in-vitro activity of all the fluoroquinolones tested was not affected by the penicillin susceptibility of the S. pneumoniae strains.
In our study, levofloxacin had an MIC 90 of 1 mg/L, which was half that of ofloxacin. This is similar to the results of Barry et al. 8 and Johnson et al. 15 who showed that levofloxacin was twice as active as ofloxacin in a study of 654 and 583 S. pneumoniae isolates, respectively. Similarly, levofloxacin was shown to be generally twice as active as ofloxacin against Gram-positive bacteria in a study of 506 strains by Eliopoulos et al. 9 Our results confirm those of other studies which have demonstrated levofloxacin's good activity against penicillin-resistant strains. [16] [17] [18] Klugman et al. 16 also compared the in-vitro activity of levofloxacin, ofloxacin, ciprofloxacin and sparfloxacin, together with D-ofloxacin, against 180 pneumococcal strains with varying susceptibility to penicillin. George & Morrissey 17 compared these five fluoroquinolones and cefotaxime against four strains, and Pankuch et al. 18 compared the in-vitro activity of six fluoroquinolones, including levofloxacin, against 112 penicillin-susceptible and penicillin-resistant pneumococciand showed that their activity was unaffected by the strain's penicillin susceptibility.
Although sparfloxacin was found to be more active than levofloxacin, ofloxacin and ciprofloxacin in this and other studies, 16, 18 George & Morrissey 17 found that levofloxacin was the most active of these fluoroquinolones. The MICs of levofloxacin and ciprofloxacin in our study were similar. This result differs from those of previously reported studies 18, 19 in which the MIC of ciprofloxacin approximated its susceptibility breakpoint for aerobic bacteria (2.0 mg/L) and those in which the MIC of levofloxacin was found to be equal to or one dilution lower than that of ciprofloxacin. [20] [21] [22] [23] In addition, previous studies have shown levofloxacin to be more active against S. pneumoniae than ciprofloxacin. [16] [17] [18] [19] Furthermore, in a lower respiratory tract infection model, levofloxacin (20 and 40 mg/kg body weight) significantly reduced the number of S. pneumoniae cells from 8.1 log U to 6.4 and 5.5 log U, while ciprofloxacin was ineffective at the same doses. 24 Markus et al. 19 have also shown that in vivo, levofloxacin was more effective than ciprofloxacin in reducing the viable counts of S. pneumoniae in the lungs in a mouse pneumonia model.
The good in-vitro activity of levofloxacin against S. pneumoniae has been confirmed by clinical studies which have shown it to be effective in the treatment of pneumococcal respiratory tract infections including sinusitis, acute exacerbations of chronic bronchitis and community-acquired pneumonia. 11, [25] [26] [27] [28] [29] In conclusion, the results of this study indicate that levofloxacin has good in-vitro activity against S. pneumoniae and has potential for the treatment of pneumococcal infections.
